{
    "nct_id": "NCT06436742",
    "official_title": "A Phase 1b, Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Adult Participants with DOK7-Congenital Myasthenic Syndromes",
    "inclusion_criteria": "* At least 18 years of age.\n* Has genetically confirmed congenital myasthenic syndromes due to mutation of downstream of kinase 7 (DOK7-CMS).\n* Participants taking oral beta agonists (eg, albuterol, salbutamol, ephedrine) must have been receiving the medication for more than 3 months and agree to remain on a same stable dosing regimen of the same medication until the end of the study.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Diagnosis of CMS due to mutation of any gene other than DOK7.\n* Known medical condition that would interfere with an accurate assessment of CMS, confound the results of the study, or put the patient at undue risk, as assessed by the investigator.\n* History of malignancy, cancer, unless considered cured by adequate treatment with no evidence of recurrence for more than 5 years. Adequately treated participants with the following cancers can be included at any time: Basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histological findings of prostate cancer.\n* Different study drug received in another clinical study within 12 weeks or 5 half-lives before screening.\n* Current participation in another interventional clinical study or prior participation in any gene therapy or cell therapy study.\n* Pregnant or lactating state or intention to become pregnant during the study.\n\nThe complete list of exclusion criteria can be found in the protocol.",
    "miscellaneous_criteria": ""
}